Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...

Morgan Stanley has initiated coverage on Hims & Hers Health, Inc. (NYSE:HIMS) with an Overweight rating and a price target of ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

CNBC’s Jim Cramer suggested on Tuesday that NVIDIA Corp. (NASDAQ:NVDA) may have reached a key turning point after the stock ...

HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth services ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped ...

Hims & Hers (HIMS) is down -12.0%, or -$3.42 to $25.13.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from ...

Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...